Combination of Ruxolitinib with Resminostat exerts antantitumor effects in a chicken embryo metastasis model

Abstract

Póster presentado en el 34th European Organisation for Research and Treatment of Cancer Symposium (EORTC), celebrado en Barcelona (España) del 26 al 28 de octubre de 2022.Elucidation of molecular targets will improve the clinical management of cutaneous T-cell lymphomas (CTCL). The combination of JAK/HDAC inhibitors exerted beneficial effects in haematological malignancies, presenting promising therapeutic CTCL targets. Our current published data (1) showed that the combination of Resminostat (HDACi) with Ruxolitinib (JAKi) had cytotoxic effect, inhibited proliferation in CTCL cell lines suggesting a strong synergy for both drugs. The drugs¿ combination inhibited phosphorylation of STAT3, Akt, ERK1/2 and JNK in MyLa, while it reduced activation of Akt and JNK in SeAx. It is challenging to explore the effect of JAK/HDACi in tumor formation, angiogenesis and metastasis in CTCL. AIMS: We used a CTCL in vivo chicken embryo model (2), in order to study the effect of Resminostat and/or Ruxolitinib in the possibility of generating primary tumors and studying its metastatic potential in a timely and cost-effective manner offering a number of unique advantages to study the multistep process of tumor cell metastasis. Thus, we generated xenografted tumors derived from MyLa and SeAx cells implanted on top of the chicken c